initiated and supervised by appropriate specialist, adjunctive treatment of partial seizures with or without secondary generalisation not satisfactorily controlled with other antiepileptics; monotherapy for management of infantile spasms (West's syndrome)
Cautions renal impairment (Appendix 3); elderly; closely monitor neurological function; avoid sudden withdrawal (taper off over 2–4 weeks); history of psychosis, depression or behavioural problems; pregnancy (see Pregnancy and breast-feeding and Appendix 4) and breast-feeding (Appendix 5); absence seizures (may be exacerbated); interactions: see Interactions in section 4.8.1 and Appendix 1 (vigabatrin)
Visual field defects Vigabatrin is associated with visual field defects. The CSM has advised that onset of symptoms varies from 1 month to several years after starting. In most cases, visual field defects have persisted despite discontinuation. Product literature advises visual field testing before treatment and at 6-month intervals; a procedure for testing visual fields in those with a developmental age of less than 9 years is available from the manufacturers. Patients should be warned to report any new visual symptoms that develop and those with symptoms should be referred for an urgent ophthalmological opinion. Gradual withdrawal of vigabatrin should be considered.
Contra-indications visual field defects
Side-effects drowsiness (rarely, encephalopathic symptoms consisting of marked sedation, stupor, and confusion with non-specific slow wave EEG—reduce dose or withdraw), fatigue, visual field defects (see also under Cautions), dizziness, nervousness, irritability, behavioural effects such as excitation and agitation especially in children; depression, abnormal thinking, headache, nystagmus, ataxia, tremor, paraesthesia, impaired concentration; less commonly confusion, aggression, psychosis, mania, memory disturbance, visual disturbance (e.g. diplopia); also weight gain, oedema, gastro-intestinal disturbances, alopecia, rash; less commonly, urticaria, occasional increase in seizure frequency (especially if myoclonic), decrease in liver enzymes, slight decrease in haemoglobin; photophobia and retinal disorders (e.g. peripheral retinal atrophy); optic neuritis, optic atrophy, hallucinations also reported